Expression of CD4 on human peripheral blood neutrophils.

Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics (2006) 3.27

Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood (2009) 2.43

Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol (2014) 1.47

First Demonstration of Antigen Induced Cytokine Expression by CD4-1+ Lymphocytes in a Poikilotherm: Studies in Zebrafish (Danio rerio). PLoS One (2015) 1.44

The CD4 molecule on CD8+ T lymphocytes directly enhances the immune response to viral and cellular antigens. Proc Natl Acad Sci U S A (2005) 0.98

CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology (2009) 0.93

γδ T Cells in HIV Disease: Past, Present, and Future. Front Immunol (2015) 0.86

Activation by inflammatory stimuli increases neutrophil binding of human immunodeficiency virus type 1 and subsequent infection of lymphocytes. J Virol (2004) 0.85

Human Blood-Circulating Basophils Capture HIV-1 and Mediate Viral trans-Infection of CD4+ T Cells. J Virol (2015) 0.83

Plasmodium falciparum infection significantly impairs placental cytokine profile in HIV infected Cameroonian women. PLoS One (2009) 0.81

Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS (2011) 0.80

Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model. Transfusion (2011) 0.80

Cytokine Gene Expression in CD4 Positive Cells of the Japanese Pufferfish, Takifugu rubripes. PLoS One (2013) 0.78

Lower omental t-regulatory cell count is associated with higher fasting glucose and lower β-cell function in adults with obesity. Obesity (Silver Spring) (2016) 0.76

HIV-1 gp120 envelope glycoprotein determinants for cytokine burst in human monocytes. PLoS One (2017) 0.75

Immunophenotype in orofacial granulomatosis with and without Crohn's disease. Med Oral Patol Oral Cir Bucal (2014) 0.75

Cancer-related inflammation. Nature (2008) 34.21

The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85

Macrophage activation and polarization. Front Biosci (2008) 11.17

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55

Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33

Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85

Macrophage polarization comes of age. Immunity (2005) 5.67

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet (2007) 5.65

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet (2009) 5.00

Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol (2012) 4.30

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 4.07

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet (2007) 4.04

Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev (2006) 4.02

The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95

A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood (2005) 3.85

Possibility that transmissible viruses might be involved in the etiology of human cancer. Rev Clin Exp Hematol (2003) 3.76

Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71

A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood (2009) 3.52

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37

The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 3.33

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. AIDS (2014) 3.25

Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 3.01

New vistas on macrophage differentiation and activation. Eur J Immunol (2007) 2.99

p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 2.76

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr (2004) 2.55

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet (2011) 2.48

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43

Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem (2005) 2.40

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37

Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol (2008) 2.26

Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet (2006) 2.14

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14

Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer (2004) 2.12

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol (2009) 2.06

International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS (2006) 1.98

Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis (2011) 1.96

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol (2002) 1.95

Pathways connecting inflammation and cancer. Curr Opin Genet Dev (2008) 1.95

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS (2009) 1.93

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87

Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes (2002) 1.84

Cellular and molecular pathways linking inflammation and cancer. Immunobiology (2009) 1.78

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis (2011) 1.77

Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol (2003) 1.75

Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol (2013) 1.67

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother (2011) 1.66

A relapsing inflammatory syndrome and active human herpesvirus 8 infection. N Engl J Med (2005) 1.63

A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc (2008) 1.60

Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood (2009) 1.59

Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem (2002) 1.55

Inflammation and cancer: breast cancer as a prototype. Breast (2007) 1.52

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50

Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol (2011) 1.50

Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol (2005) 1.47

Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis (2005) 1.47

Rapid diagnosis of mycobacterial infections and quantitation of Mycobacterium tuberculosis load by two real-time calibrated PCR assays. J Clin Microbiol (2003) 1.46

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45

Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood (2002) 1.45

Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS (2007) 1.44

Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol (2004) 1.43

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS (2006) 1.41

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis (2007) 1.39

[Results of combined therapy in rectal cancer]. Chir Ital (2005) 1.38

Recognition of RANTES by extracellular parts of the CCR5 receptor. J Mol Biol (2006) 1.35

Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35

Virological rebound after suppression on highly active antiretroviral therapy. AIDS (2003) 1.34

Role of arginine metabolism in immunity and immunopathology. Immunobiology (2007) 1.33

Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol (2013) 1.33

Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids. J Clin Microbiol (2002) 1.32

Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol (2007) 1.31

Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31

Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher (2005) 1.30

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS (2013) 1.29

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS (2004) 1.28

Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. J Infect Dis (2006) 1.28

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest (2002) 1.26

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS (2013) 1.26

Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo. J Virol (2003) 1.25

Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr (2003) 1.25

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS (2009) 1.25

The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol (2003) 1.23

Divergent effects of hypoxia on dendritic cell functions. Blood (2008) 1.20

Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab (2002) 1.19

Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol (2003) 1.18

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr (2010) 1.17